Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Analysts at Goldman Sachs turned bearish on industry giant Johnson & Johnson (NYSE:JNJ) amid valuation concerns. Analyst Jami Rubin downgraded J&J's stock from Neutral to Sell with a price target boosted from $125 to $130, which implies downside from Wednesday's open of $133.25.
The decision to turn negative on J&J's stock is largely based on relative value, the analyst explained. Specifically, the company has been one of the largest beneficiaries of an ongoing rotation into defensive categories like the broader healthcare sector. Since July of 2015, shares gained 37 which marks outperformance versus the S&P 500 index (up 21 percent), the healthcare ETF, Health Care SPDR (ETF) (NYSE:XLV) (up 9 percent), and other large-cap pharma stocks that are higher on average by 6 percent.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
As such, there's a risk that investors will be rotating into other pharmaceutical stocks, especially those that boast a more attractive product cycle, Rubin suggested. As for J&J, the company has a lack of optionality for value creation versus its peers, especially in terms of high value pipeline assets, transformative M&A and operating leverage.
Investors may be better off buying shares of AbbVie Inc (NYSE:ABBV), Bristol-Myers Squibb Co (NYSE:BMY) and/or Eli Lilly and Co (NYSE:LLY), the analyst suggested. These three companies are attractive for their "more identifiable, needle moving catalysts."
Bottom line, J&J's below-average, long-term growth outlook implies that its valuation today is "stretched."
Related Links:
Your Easy Guide To Credit Suisse's New Top Stocks List
Johnson & Johnson Management Meetings Leave UBS Reiterating Stock As A Top Pick
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.